LOGIN JOIN SHARECAFE SIGN UP FOR OUR NEWSLETTER ADVERTISE
share cafe logo  
 
SHARECAFE COMMENTARY

Earnings Update Spurs Sirtex
BY GLENN DYER - 18/01/2018 | VIEW MORE ARTICLES BY GLENN DYER

Get More Commentary, Discussion & Market Information On -

SRX - SIRTEX MEDICAL LIMITED


Suddenly investors want Sirtex Medical shares.

In fact there’s nothing surprisingly good news from a company down in the books of investors, to reignite interest, and the share price.

The disappointments of 2017 with a poor trial and big write-downs and losses were forgotten yesterday.

Sirtex provided the stimulation yesterday for a 16% surge in its share price at one stage in the session.

The liver cancer treatment specialist flagged improved first-half earnings and a turnaround in second-half sales and off went the shares in a run that took them to a day’s high of $18.68, the highest they have been for around 9 months. They closed up 13.9% at $17.83

The company, which reported a $26.3 million loss for 2016-17 after write downs and failed clinical trials, told the market it now expects underlying first-half earnings for 2017-18 of $34 million - up 16% improvement on the previous first half.

Sales of the company’s SIR-Spheres microspheres - a product used to deliver medication to cancer sites inside the body - were flat in the first half but Sirtex CEO Andrew McLean, who took up his role in May, said the company expects higher sales in the June, 2018 half year.

“As a result of recent management initiatives, we anticipate higher sales in the second half, with ongoing targeted reductions in operating expenditure to drive business efficiencies and productivity gains, resulting in forecast full year EBITDA in the range of $75-85 million,” Mr McLean said yesterday's statement.

Underlying earnings were $61.5 million in 2016-17.

Sirtex suffered slowing sales growth last year, including in its key US market, and the company took a $90.5 million writedown on research and development assets after a disappointing clinical trial result in May.



View More Articles By Glenn Dyer

Glenn Dyer has been a finance journalist and TV producer for more than 40 years. He has worked at Maxwell Newton Publications, Queensland Newspapers, AAP, The Australian Financial Review, The Nine Network and Crikey.

At the AFR he was a finance writer, Finance Editor, News Editor and Chief of Staff. At the Nine Network he was supervising producer of Business Sunday for more than 16 years. He has also written for other online and analogue print publications here and overseas.



 

RECENTLY ADDED TO SHARECAFE


 › Marcus Today End Of Day Report
 › Friday At The Close
 › Dacian Set For Share Price Re-Rating
 › Can An Investor Profit From M&A Activity?
 › Market At Midday On Friday
 › Right Place, WRONG Time
 › Next Week At A Glance
 › Overnight: It's Off
 › EHL - Morgans rates the stock as Add
 › REA - Citi rates the stock as Buy
 › WES - Macquarie rates the stock as No Rating
 › Italy Is A Worry - But 3 Reasons Not To Be Concerned About An Itexit
 › Digital Growth Spins Aristocrat Higher
 › Shareholders Seal Westfield Takeover
More ShareCafe   

GET THE SHARECAFE BREAKFAST BRIEFING


Delivered free to your inbox before the market opens each trading day. Sign up below +

SHARECAFE VIDEO


Wilson moves into Global Equities

More video